Research - Every stock has its day. Ariad Pharmaceuticals (ARIA) has had a few. From safety issues with its only marketed product Iclusig in 2014, that sent the stock reeling from $20 to $2, to repeat takeover rumors over the last few years that sent the stock soaring.
PremiumResearch - With Allergan (AGN) and Pfizer (PFE) calling off plans to merge this week, the biotech sector rallied in a big way. Why? In part, Allergan … Continue Reading
Read nowResearch - Put simply, appetites for healthcare equities are in short supply, and as we’ve been discussing, it makes sense to be prepared for a reversion to the mean for the sector. This has been/is slowly playing out.
PremiumResearch - Equities remain linked at the hip to the fluctuations in oil, and Thursday marked the first meaningful decoupling in the last month. According to the Wall Street Journal, over the past 20 trading days (one month) the correlation has been 0.97, the highest in 26 years.
PremiumResearch - Cellectis/treating physicians will discuss the first-in-human experience with UCART19, the company's allogeneic CD-19 targeted CAR-T asset, at ASH. And, they may be able to discuss results in more than one patient.
PremiumResearch - The recovery is slowly underway in the land of biotech, and these equities are getting a lift from Pfizer's (PFE) planned merger with Allergan (AGN), announced Monday.
Read nowResearch - Bellicum Pharmaceuticals (BLCM) after the bell this evening reported third quarter earnings, but more importantly noted that four pediatric beta-thalassemia patients who underwent HSCT followed by BPX-501 modified T cells are transfusion-free.
Premium
